drugset / Trial / NCT02212782
the Pharmacokinetic Profiles of Linagliptin With DW1029M
RandomizedCrossoverOpen-labelHealth-services research
Summary
Phase I clinical study to evaluate DW1029M influence the pharmacokinetic profiles of Linagliptin after oral administration in healthy male volunteer.
Timeline
- Start
- 2014-09
- Primary completion
- 2014-11
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DW1029M | Unknown | 600 mg | Oral |
| Subject | Linagliptin | Small molecule | 5 mg | Oral |
Indications
No indication recorded.